Specifically, anti-programmed cell death protein 1 (PD-1) antibodies have shown durable anticancer immunity and longer survival in patients with untreated metastatic GC who have microsatellite instability-high or deficient mismatch repair [19]. The gene discussed is PDCD1; the disease is gastric cancer.